News

CORONA Remedies Limited will hold a board meeting on Friday, October 30, 2026, to consider and approve the unaudited financial results (standalone and consolidated) for the second quarter and half year ended September 30, 2026, and other business matters. The trading window for dealing in the company`s securities will remain closed until Sunday, November 01, 2026, as previously communicated on September 28, 2026.

Corona Remedies Limited informed the BSE Limited and National Stock Exchange of India that Bigshare Services Private Limited, the company`s Registrar to Issue and Share Transfer Agent, has confirmed the non-applicability of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, as all shares are held in demat form and no requests for rematerialization or dematerialization were received.

CORONA Remedies Limited informed the BSE Limited and National Stock Exchange of India Limited that the trading window for dealing in the company`s securities will be closed from October 01, 2026, until 48 hours after the declaration of the unaudited financial results for the second quarter and half year ending September 30, 2026, in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

Net profit of Corona Remedies rose 30.11% to Rs 60.11 crore in the quarter ended June 2026 as against Rs 46.20 crore during the previous quarter ended June 2025. Sales rose 21.90% to Rs 422.43 crore in the quarter ended June 2026 as against Rs 346.54 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales422.43346.54 22 OPM %22.0520.08 - PBDT93.6069.61 34 PBT80.3660.69 32 NP60.1146.20 30 Powered by Capital Market - Live News

Corona Remedies will hold a meeting of the Board of Directors of the Company on 31 July 2026.